According to our calculations, a $1000 investment made in January 2015 would be worth $3,848.25, or a 284.82% gain, as of January 9, 2025. Investors should keep in mind that this return excludes ...

Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full ...

Halozyme announced that Argenx’s Vyvdura, which is co-formulated with Halozyme’s Enhanze drug delivery technology, was granted regulatory approval by Japan’s Ministry of Hea ...

Halozyme (HALO) announced that Bristol Myers Squibb (BMY) received FDA approval for Opdivo Qvantig co-formulated with Halozyme’s Enhanze drug ...

SAN DIEGO, Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is co-formulated ...

"We are pleased that VYVDURA, with our innovative ENHANZE drug delivery technology, is now approved for two indications in Japan, enabling greater flexibility and optionality for generalized ...

Becomes the first subcutaneously administered PD-1 inhibitor.

SAN DIEGO, Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is co ...

Halozyme (HALO) announced that Argenx’s (ARGX) Vyvdura, which is co-formulated with Halozyme’s Enhanze drug delivery technology, was granted regulatory approval by Japan’s Ministry of Health ...